ELOX Eloxx Pharmaceuticals, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1035354 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-38.6%
ROA-27.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets29.5%
Debt / equity0.00x
Current ratio3.39x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.17x
Accruals ratio4.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2023Q4*2023-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $4.03M | $2.84M | $1.66M | $1.90M | -$250,000 | $898,000 | $510,000 | $1.52M |
| SG&A expense | $1.93M | $1.61M | $2.14M | $1.45M | $535,000 | $684,000 | $712,000 | $2.51M |
| Operating income | -$5.95M | -$4.45M | -$3.79M | -$3.35M | -$285,000 | -$1.58M | -$1.22M | -$4.03M |
| Interest expense | $100,000 | $100,000 | $100,000 | — | $200,000 | $300,000 | $500,000 | — |
| Net income | -$5.54M | -$4.50M | -$3.75M | -$2.04M | -$351,000 | -$1.89M | -$1.71M | -$2.89M |
| EBITDA | — | — | — | — | — | — | — | -$3.96M |
| EPS (basic) | -0.49 | -0.66 | -0.08 | — | -0.58 | -5.45 | -0.45 | — |
| EPS (diluted) | -0.49 | -0.66 | -0.08 | — | -0.58 | -5.45 | -0.45 | — |
| Weighted avg. shares (diluted) | 11.40M | 6.79M | 48.21M | — | 604,278 | 347,000 | 3.81M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $56.26M | $61.96M | $6.36M | $4.79M | $4.21M | $572,000 | $450,000 | $1.13M |
| Current assets | $58.26M | $63.39M | $8.50M | $5.27M | — | — | — | $1.55M |
| PP&E, net | — | — | — | $0 | — | — | — | $35,000 |
| Total assets | $58.26M | $63.39M | $8.50M | $5.27M | — | — | — | $1.71M |
| Current liabilities | $17.19M | $16.97M | $16.09M | $17.18M | — | — | — | $22.70M |
| Short-term debt | $0 | $0 | $0 | $1.00M | — | — | — | $2.22M |
| Long-term debt | — | — | — | $0 | — | — | — | $1.61M |
| Total debt | — | — | — | $1.00M | — | — | — | $3.83M |
| Total liabilities | $17.19M | $16.97M | $16.09M | $17.18M | — | — | — | $24.31M |
| Shareholders' equity | $41.07M | $46.42M | -$7.58M | -$11.91M | -$14.99M | -$27.90M | -$26.02M | -$22.60M |
| Net debt | — | — | — | -$3.79M | — | — | — | $2.70M |
| Shares outstanding | 4.09M | 4.04M | 5.07M | 435,432 | — | — | — | 3.14M |
| Cash flow statement | ||||||||
| Operating cash flow | -$4.28M | -$4.79M | -$5.45M | -$4.06M | -$1.72M | -$1.75M | $1.20M | -$2.01M |
| Investing cash flow | — | — | — | — | — | — | — | $51,000 |
| Financing cash flow | -$1.42M | $60.39M | $7.03M | $4.64M | $5.35M | $1.88M | -$865,000 | -$1.68M |
| Depreciation & amortization | — | — | — | — | — | — | — | $73,000 |
| Stock-based compensation | $190,000 | $95,000 | $46,000 | $189,000 | $10,000 | $16,000 | $20,000 | $340,000 |
Free plan shows the latest 8 periods; Pro shows all 61 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.